CTMC, a joint venture between Resilience and MD Anderson Cancer Center, has entered into a collaborative partnership with Einstein Hospital Israelita in Sao Paulo, Brazil, aimed at accelerating the adoption of cell therapy in Brazil and all of Latin America.
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.
